PDC Biotech plans trial of peptide to treat primary dysmenorrhoea
This article was originally published in Scrip
PDC Biotech, a privately held Austrian biopharmaceutical development company, is about to start a Phase I trial of PDC31 to treat otherwise healthy women with primary dysmenorrhoea, a disabling condition found in 10-15% of women of childbearing age which causes severe abdominal pain. The Phase I trial will be conducted at three clinical sites in Austria and in Germany and will evaluate the safety and pharmacokinetics of the compound as well as its effects on uterine contractility.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.